Պրիվիգեն

main_info

  • trade_name:
  • Պրիվիգեն
  • dosage:
  • 100մգ/մլ200մլ ապակե սրվակ
  • pharmaceutical_form:
  • լուծույթ կաթիլաներարկման
  • prescription_type:
  • Դեղատոմսով
  • medicine_domain:
  • Human
  • medicine_type:
  • Allopathic

documents

localization

  • country:
  • Պրիվիգեն
    አርሜኒያ
  • language:
  • አማርኛ

other_info

status

  • source:
  • Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում - Armenia
  • last_update:
  • 31-05-2018

24-8-2018

Imagine recalls Buckyballs magnet sets

Imagine recalls Buckyballs magnet sets

Health Canada has determined that these magnet sets are a danger to human health and safety because they contain small powerful magnets which can be easily swallowed or inhaled by children. Unlike other small objects that would be more likely to pass normally through the digestive system if swallowed, when more than one small powerful magnet is swallowed, the magnets can attract one another while travelling through the digestive system. The magnets can then pinch together and create a blockage and slowly...

Health Canada

7-3-2019

Kiovig (Baxter AG)

Kiovig (Baxter AG)

Kiovig (Active substance: Human normal immunoglobulin (IVIg)) - Centralised - 2-Monthly update - Commission Decision (2019)1909 of Thu, 07 Mar 2019 European Medicines Agency (EMA) procedure number: EMEA/H/C/628/IB/88

Europe -DG Health and Food Safety

25-2-2019


Orphan designation: Ex vivo fused normal allogeneic human myoblast with another normal allogeneic human myoblast, Treatment of Duchenne muscular dystrophy, 19/11/2018, Positive

Orphan designation: Ex vivo fused normal allogeneic human myoblast with another normal allogeneic human myoblast, Treatment of Duchenne muscular dystrophy, 19/11/2018, Positive

Orphan designation: Ex vivo fused normal allogeneic human myoblast with another normal allogeneic human myoblast, Treatment of Duchenne muscular dystrophy, 19/11/2018, Positive

Europe - EMA - European Medicines Agency

25-2-2019


Orphan designation: Ex vivo fused normal allogeneic human myoblast with autologous human myoblast derived from Duchenne muscular dystrophy affected donor, Treatment of Duchenne muscular dystrophy, 19/11/2019, Positive

Orphan designation: Ex vivo fused normal allogeneic human myoblast with autologous human myoblast derived from Duchenne muscular dystrophy affected donor, Treatment of Duchenne muscular dystrophy, 19/11/2019, Positive

Orphan designation: Ex vivo fused normal allogeneic human myoblast with autologous human myoblast derived from Duchenne muscular dystrophy affected donor, Treatment of Duchenne muscular dystrophy, 19/11/2019, Positive

Europe - EMA - European Medicines Agency

4-2-2019

Privigen (CSL Behring GmbH)

Privigen (CSL Behring GmbH)

Privigen (Active substance: Human normal immunoglobulin (IVIg)) - Centralised - 2-Monthly update - Commission Decision (2019)841 of Mon, 04 Feb 2019 European Medicines Agency (EMA) procedure number: EMEA/H/C/831/IB/144

Europe -DG Health and Food Safety

15-1-2019

Hizentra (CSL Behring GmbH)

Hizentra (CSL Behring GmbH)

Hizentra (Active substance: human normal immunoglobulin) - Centralised - 2-Monthly update - Commission Decision (2019)195 of Tue, 15 Jan 2019 European Medicines Agency (EMA) procedure number: EMEA/H/C/2127/II/97G

Europe -DG Health and Food Safety

12-12-2018


Scientific recommendation on classification of advanced therapy medicinal products: Dystrophin expressing chimeric cells obtained by ex vivo fusion of two normal allogeneic human myoblasts

Scientific recommendation on classification of advanced therapy medicinal products: Dystrophin expressing chimeric cells obtained by ex vivo fusion of two normal allogeneic human myoblasts

Scientific recommendation on classification of advanced therapy medicinal products: Dystrophin expressing chimeric cells obtained by ex vivo fusion of two normal allogeneic human myoblasts

Europe - EMA - European Medicines Agency

21-11-2018

EU/3/18/2089 (Dystrogen Therapeutics S.A.)

EU/3/18/2089 (Dystrogen Therapeutics S.A.)

EU/3/18/2089 (Active substance: Ex vivo fused normal allogeneic human myoblast with autologous human myoblast derived from Duchenne muscular dystrophy affected donor) - Orphan designation - Commission Decision (2018)7798 of Wed, 21 Nov 2018

Europe -DG Health and Food Safety

21-11-2018

EU/3/18/2088 (Dystrogen Therapeutics S.A.)

EU/3/18/2088 (Dystrogen Therapeutics S.A.)

EU/3/18/2088 (Active substance: Ex vivo fused normal allogeneic human myoblast with another normal allogeneic human myoblast) - Orphan designation - Commission Decision (2018)7797 of Wed, 21 Nov 2018 European Medicines Agency (EMA) procedure number: EMA/OD/134/18

Europe -DG Health and Food Safety